Open access · OA
via OpenAlex
Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia
Andrew P. Merluzzi, Cynthia M. Carlsson, Sterling C. Johnson, Suzanne E. Schindler, Sanjay Asthana, Kaj Blennow, Henrik Zetterberg, Barbara B. Bendlin
Neurology · 2018 · ▲ 49 citations
Abstract
Objective To test the hypothesis that cognitively unimpaired individuals with Alzheimer disease (AD) neuropathology differ from individuals with AD dementia on biomarkers of neurodegeneration, synaptic dysfunction, and glial activation. Methods In a cross-sectional study, adult participants >70 years old (n = 79, age 77.1 ± 5.3 years) underwent comprehensive cognitive evaluation and CSF collection, which was assayed for markers of amyloid, phosphorylated tau (p-tau), neurodegeneration (neurofilament light protein [NFL] and total tau), synaptic dysfunction (neurogranin), and glial activation (chitinase-3–like protein 1 [YKL-40]). Participants were divided into 3 groups based on diagnosis and p-tau/β-amyloid42 (Aβ42): those with low p-tau/Aβ42 and unimpaired cognition were classified as controls (n = 25); those with high p-tau/Aβ42 diagnosed with AD-dementia or AD–mild cognitive impairment were classified as AD-Dementia (n = 40); and those with high p-tau/Aβ42 but unimpaired cognition were classified as mismatches (n = 14). A similar, secondary analysis was performed with no age exclusion criteria (n = 411). Results In both the primary and secondary analyses, biomarker levels between groups were compared with the use of analysis of covariance while controlling for age and demographic variables. Despite p-tau/Aβ42 and Aβ42/Aβ40 levels comparable to those of the AD-Dementia group, mismatches had significantly lower levels of NFL and total tau. While not significantly lower than the AD-Dementia group on YKL-40 and neurogranin, mismatches were also not significantly different from controls. Conclusions These results provide evidence that, in the absence of significant neurodegenerative processes, individuals who harbor AD neuropathology may remain cognitively unimpaired. This finding provides insight into the biological processes phenotypic of dementia and supports monitoring multiple biomarkers in individuals positive for AD neuropathology.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1212/wnl.0000000000005901
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Merluzzi, A.P., Carlsson, C.M., Johnson, S.C., Schindler, S.E., Asthana, S., Blennow, K., Zetterberg, H., & Bendlin, B.B. (2018). Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. <em>Neurology</em>. https://doi.org/10.1212/wnl.0000000000005901
Vancouver
Merluzzi AP, Carlsson CM, Johnson SC, Schindler SE, Asthana S, Blennow K, et al. Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia. Neurology. 2018. doi:10.1212/wnl.0000000000005901.
BibTeX
@article{andrew2018Neurod,
title = {Neurodegeneration, synaptic dysfunction, and gliosis are phenotypic of Alzheimer dementia},
author = {Andrew P. Merluzzi and Cynthia M. Carlsson and Sterling C. Johnson and Suzanne E. Schindler and Sanjay Asthana and Kaj Blennow and Henrik Zetterberg and Barbara B. Bendlin},
journal = {Neurology},
year = {2018},
doi = {10.1212/wnl.0000000000005901},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Alzheimer s Research & Therapy 2018
Open access · CC-BY
Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
Medical College of Wisconsin 2009
Open access · US-GOV
A Composite MR Neuroimaging Marker for Alzheimer's Disease
GeroScience 2025
Open access · CC-BY
Unraveling the link between frailty and Alzheimer’s disease biomarkers in patients with mild cognitive impairment
JAMA Neurology 2019
Open access · OA
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
Eli Lilly and Company 2026
Open access · US-GOV
A Master Protocol for Phase 1 Clinical Trials of Multiple Amyloid-Targeting Therapies for the Treatment of Alzheimer's Disease
University Hospital, Tours 2021
Open access · US-GOV